$Genetic Technologies (GENE.US)$ Notice of Delisting from Nasdaq.Melbourne Australia, 13 December, 2024: Genetic Technologies Limited (Administrators Appointed) (ASX: GTG; NASDAQ: GENE) (“Genetic Technologies” or the “Company”) advices that the Company has received a Delisting Notice from Nasdaq Stock Market LLC (“Nasdaq”)relating, amo...
NOTE: Whenever a stock is up, make sure you check its dilution risk - cash on hand because most likely if they are cash-strapped, they will make offering. Scaling out is key. NEVER listen to those who say hold on because if you lose money, they wouldnt care AT ALL. ************************************* REVERSE...
$Genetic Technologies (GENE.US)$Notice of Delisting from Nasdaq and Failure to Satisfy a Continued Listing Rule or Standard. Melbourne Australia, December 12, 2024: Genetic Technologies Limited (Administrators Appointed) (ASX: GTG; NASDAQ: GENE) (“Genetic Technologies” or the “Company”) previously announced on November 20, 2024 that Ross Blakeley and Paul Harlond of FTI Consulting had been appointed as Joint and Several Voluntary Administrators (“Administrators”) pursuant to section 436A...
1
20
Report
Jaguar8
:
Another possible delisting play before Tuesday. Tomorrow or Monday but not delisted on ASX
$Genetic Technologies (GENE.US)$Genetic Technologies Launches Personalized Risk Testing on EasyDNA Platform MT Newswires· Genetic Technologies (ASX:GTG) launched the geneType Risk Assessment portfolio on its EasyDNA platform, according to a Thursday filing with the Australian Securities Exchange. The availability of geneType on EasyDNA's consumer platform is expected to accelerate global access, potentially reaching 42 countries and generating annual revenues of AU$7.5 million, the filing sa...
2
2
Report
Arrayfunction
:
I was going to say this seemed kinda strange because the US regulators (more FTC than FDA) have always been very strict in how genetic testing companies can advertise and present "health" information. (e.g. 23andme has "pre-dispositions" on "influencing the probability of developing" certain issues). And a quick Google seems to agree with that - only the sperm related testing is actually coming to the US market. Which might explain why I have only heard of the brand in the context of paternity testing It will be interesting to see if this is the start of the US letting consumers have more direct access to that kind of information. I am more keen to agree that it's better overall to limit public consumer access. I haven't kept up with the field in the past decade, but around that time was when the importance of epigenomics and transcriptomics to be shown as playing a significant, if not greater, influence on actual phenotype than strictly genes.
Genetic Technologies Stock Forum
Notice of Delisting from Nasdaq.Melbourne Australia, 13 December, 2024: Genetic Technologies Limited (Administrators Appointed) (ASX: GTG; NASDAQ: GENE) (“Genetic Technologies” or the “Company”) advices that the Company has received a Delisting Notice from Nasdaq Stock Market LLC (“Nasdaq”)relating, amo...
*************************************
REVERSE...
Melbourne Australia, December 12, 2024: Genetic Technologies Limited (Administrators Appointed) (ASX: GTG; NASDAQ: GENE) (“Genetic Technologies” or the “Company”) previously announced on November 20, 2024 that Ross Blakeley and Paul Harlond of FTI Consulting had been appointed as Joint and Several Voluntary Administrators (“Administrators”) pursuant to section 436A...
MT Newswires·
Genetic Technologies (ASX:GTG) launched the geneType Risk Assessment portfolio on its EasyDNA platform, according to a Thursday filing with the Australian Securities Exchange.
The availability of geneType on EasyDNA's consumer platform is expected to accelerate global access, potentially reaching 42 countries and generating annual revenues of AU$7.5 million, the filing sa...
NEWS
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
NEWS
Genetic Technologies Announces $2 Million Registered Direct Offering
3 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
No comment yet